Literature DB >> 16267837

Cell cycle control in breast cancer cells.

C Elizabeth Caldon1, Roger J Daly, Robert L Sutherland, Elizabeth A Musgrove.   

Abstract

In breast cancer, cyclins D1 and E and the cyclin-dependent kinase inhibitors p21 (Waf1/Cip1)and p27 (Kip1) are important in cell-cycle control and as potential oncogenes or tumor suppressor genes. They are regulated in breast cancer cells following mitogenic stimuli including activation of receptor tyrosine kinases and steroid hormone receptors, and their deregulation frequently impacts on breast cancer outcome, including response to therapy. The cyclin-dependent kinase inhibitor p16 (INK4A) also has a critical role in transformation of mammary epithelial cells. In addition to their roles in cell cycle control, some of these molecules, particularly cyclin D1, have actions that are not mediated through regulation of cyclin-dependent kinase activity but may be important for loss of proliferative control during mammary oncogenesis. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16267837     DOI: 10.1002/jcb.20690

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  69 in total

1.  A novel knowledge-driven systems biology approach for phenotype prediction upon genetic intervention.

Authors:  Rui Chang; Robert Shoemaker; Wei Wang
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2011 Sep-Oct       Impact factor: 3.710

Review 2.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 3.  Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Virginia G Kaklamani; William J Gradishar
Journal:  Oncologist       Date:  2017-03-17

4.  Role of LM23 in cell proliferation and apoptosis and its expression during the testis development.

Authors:  Qing Liu; Ya-Juan Song; Li-Jun Meng; Fen Hu; Li-Xia Gou; Chang-Hong Jia; Hong-Mei Tang; Wei-Jie Wang; Mi Li; Xiu-Jun Zhang; Meng-Chun Jia
Journal:  Asian J Androl       Date:  2013-05-20       Impact factor: 3.285

Review 5.  Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Authors:  Johannes Ettl
Journal:  Breast Care (Basel)       Date:  2016-06-23       Impact factor: 2.860

6.  Integrative gene set analysis of multi-platform data with sample heterogeneity.

Authors:  Jun Hu; Jung-Ying Tzeng
Journal:  Bioinformatics       Date:  2014-01-30       Impact factor: 6.937

7.  Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.

Authors:  Maike Zimmermann; Aruni P S Arachchige-Don; Michaela S Donaldson; Tommaso Patriarchi; Mary C Horne
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 8.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

9.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors:  Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  NetDecoder: a network biology platform that decodes context-specific biological networks and gene activities.

Authors:  Edroaldo Lummertz da Rocha; Choong Yong Ung; Cordelia D McGehee; Cristina Correia; Hu Li
Journal:  Nucleic Acids Res       Date:  2016-03-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.